Intermittent treatment with pimecrolimus over 1 year significantly reverses corticosteroid-induced skin atrophy and ...

Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) is one of the most promising stocks according to Wall Street analysts. On June 26, ...

A new analysis from US data analytics firm Phesi has raised concerns about the viability of ongoing Phase III trials in ...

Apogee Therapeutics, Inc.'s APG777 shows promising week-16 efficacy and dosing potential, targeting the AT market. Click for ...

Apogee Therapeutics (NASDAQ:APGE) stock drops despite mid-stage trial success for APG777 in treating atopic dermatitis. Read ...

[A]lthough our findings found that there is insufficient evidence to suggest that dupilumab use is associated with joint pain, the prevalence of joint pain observed among patients treated with ...

AD and psoriasis were once thought to be opposites in terms of immune response, with AD linked to a Th2-dominant pathway and ...

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

Young patients with atopic dermatitis prioritize different treatment goals and have varying preferences from their caregivers.

The best shower temperature for your health depends on your goals. Experts recommend showering in lukewarm water, but there ...

The atopic dermatitis therapeutics market is poised for steady growth, with revenues projected to rise from USD 15.43 billion in 2024 to USD 29.5 billion by 2033. This reflects a compound annual ...

New data reveals sponsors risk wasting billions by designing overly complex trials and repeatedly recruiting from oversaturated investigator sites Boston, US. 9 July, 2025. Dr. Gen Li, CEO of Phesi, a ...